vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and OLAPLEX HOLDINGS, INC. (OLPX). Click either name above to swap in a different company.
OLAPLEX HOLDINGS, INC. is the larger business by last-quarter revenue ($105.1M vs $86.8M, roughly 1.2× IOVANCE BIOTHERAPEUTICS, INC.). On growth, IOVANCE BIOTHERAPEUTICS, INC. posted the faster year-over-year revenue change (17.7% vs 4.3%). OLAPLEX HOLDINGS, INC. produced more free cash flow last quarter ($32.6M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 3.1%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Olaplex Holdings, Inc. is a specialty beauty company developing and selling patented bond-repair hair care products. It runs three core segments: professional salon distribution, direct-to-consumer sales, and third-party retail, serving customers across North America, Europe, and Asia-Pacific with products that repair and protect damaged hair.
IOVA vs OLPX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $105.1M |
| Net Profit | — | $-13.1M |
| Gross Margin | 67.4% | 68.0% |
| Operating Margin | -84.7% | -4.3% |
| Net Margin | — | -12.5% |
| Revenue YoY | 17.7% | 4.3% |
| Net Profit YoY | — | -48.9% |
| EPS (diluted) | — | $-0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $105.1M | ||
| Q3 25 | $67.5M | $114.6M | ||
| Q2 25 | $60.0M | $106.3M | ||
| Q1 25 | $49.3M | $97.0M | ||
| Q4 24 | $73.7M | $100.7M | ||
| Q3 24 | $58.6M | $119.1M | ||
| Q2 24 | $31.1M | $103.9M | ||
| Q1 24 | $715.0K | $98.9M |
| Q4 25 | — | $-13.1M | ||
| Q3 25 | $-91.3M | $11.1M | ||
| Q2 25 | $-111.7M | $-7.7M | ||
| Q1 25 | $-116.2M | $465.0K | ||
| Q4 24 | — | $-8.8M | ||
| Q3 24 | $-83.5M | $14.8M | ||
| Q2 24 | $-97.1M | $5.8M | ||
| Q1 24 | $-113.0M | $7.7M |
| Q4 25 | 67.4% | 68.0% | ||
| Q3 25 | 43.0% | 69.1% | ||
| Q2 25 | 5.5% | 71.2% | ||
| Q1 25 | -0.8% | 69.5% | ||
| Q4 24 | 68.7% | 66.3% | ||
| Q3 24 | 46.2% | 68.6% | ||
| Q2 24 | -0.8% | 69.7% | ||
| Q1 24 | — | 72.1% |
| Q4 25 | -84.7% | -4.3% | ||
| Q3 25 | -140.7% | 3.7% | ||
| Q2 25 | -189.8% | -1.1% | ||
| Q1 25 | -245.8% | 8.7% | ||
| Q4 24 | -117.5% | 3.0% | ||
| Q3 24 | -152.1% | 23.5% | ||
| Q2 24 | -327.6% | 15.7% | ||
| Q1 24 | -16464.6% | 19.8% |
| Q4 25 | — | -12.5% | ||
| Q3 25 | -135.3% | 9.7% | ||
| Q2 25 | -186.2% | -7.3% | ||
| Q1 25 | -235.5% | 0.5% | ||
| Q4 24 | — | -8.7% | ||
| Q3 24 | -142.7% | 12.4% | ||
| Q2 24 | -312.2% | 5.6% | ||
| Q1 24 | -15800.8% | 7.8% |
| Q4 25 | — | $-0.02 | ||
| Q3 25 | — | $0.02 | ||
| Q2 25 | $-0.33 | $-0.01 | ||
| Q1 25 | $-0.36 | $0.00 | ||
| Q4 24 | $-0.24 | $-0.01 | ||
| Q3 24 | $-0.28 | $0.02 | ||
| Q2 24 | $-0.34 | $0.01 | ||
| Q1 24 | $-0.42 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $318.7M |
| Total DebtLower is stronger | — | $352.3M |
| Stockholders' EquityBook value | $698.6M | $879.4M |
| Total Assets | $913.2M | $1.5B |
| Debt / EquityLower = less leverage | — | 0.40× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $318.7M | ||
| Q3 25 | $300.8M | $286.4M | ||
| Q2 25 | $301.2M | $289.3M | ||
| Q1 25 | $359.7M | $580.9M | ||
| Q4 24 | $323.8M | $586.0M | ||
| Q3 24 | $397.5M | $538.8M | ||
| Q2 24 | $412.5M | $507.9M | ||
| Q1 24 | $356.2M | $507.5M |
| Q4 25 | — | $352.3M | ||
| Q3 25 | — | $352.1M | ||
| Q2 25 | — | $351.9M | ||
| Q1 25 | — | $649.1M | ||
| Q4 24 | — | $650.5M | ||
| Q3 24 | — | $651.8M | ||
| Q2 24 | — | $653.1M | ||
| Q1 24 | — | $654.4M |
| Q4 25 | $698.6M | $879.4M | ||
| Q3 25 | $702.3M | $888.7M | ||
| Q2 25 | $698.5M | $874.2M | ||
| Q1 25 | $767.9M | $878.3M | ||
| Q4 24 | $710.4M | $874.4M | ||
| Q3 24 | $773.5M | $879.7M | ||
| Q2 24 | $768.5M | $863.3M | ||
| Q1 24 | $680.0M | $855.7M |
| Q4 25 | $913.2M | $1.5B | ||
| Q3 25 | $904.9M | $1.5B | ||
| Q2 25 | $907.4M | $1.5B | ||
| Q1 25 | $966.7M | $1.8B | ||
| Q4 24 | $910.4M | $1.8B | ||
| Q3 24 | $991.1M | $1.8B | ||
| Q2 24 | $964.3M | $1.8B | ||
| Q1 24 | $869.8M | $1.8B |
| Q4 25 | — | 0.40× | ||
| Q3 25 | — | 0.40× | ||
| Q2 25 | — | 0.40× | ||
| Q1 25 | — | 0.74× | ||
| Q4 24 | — | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.76× | ||
| Q1 24 | — | 0.76× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $32.7M |
| Free Cash FlowOCF − Capex | $-61.9M | $32.6M |
| FCF MarginFCF / Revenue | -71.3% | 31.0% |
| Capex IntensityCapex / Revenue | 10.7% | 0.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $58.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $32.7M | ||
| Q3 25 | $-78.7M | $8.0M | ||
| Q2 25 | $-67.4M | $20.9M | ||
| Q1 25 | $-103.7M | $-2.9M | ||
| Q4 24 | $-73.3M | $49.7M | ||
| Q3 24 | $-59.0M | $33.5M | ||
| Q2 24 | $-98.4M | $16.2M | ||
| Q1 24 | $-122.3M | $43.7M |
| Q4 25 | $-61.9M | $32.6M | ||
| Q3 25 | $-89.5M | $7.9M | ||
| Q2 25 | $-74.9M | $20.8M | ||
| Q1 25 | $-109.9M | $-3.0M | ||
| Q4 24 | $-77.5M | $49.2M | ||
| Q3 24 | $-61.3M | $33.3M | ||
| Q2 24 | $-98.9M | $16.1M | ||
| Q1 24 | $-126.5M | $43.3M |
| Q4 25 | -71.3% | 31.0% | ||
| Q3 25 | -132.7% | 6.9% | ||
| Q2 25 | -124.9% | 19.6% | ||
| Q1 25 | -222.8% | -3.1% | ||
| Q4 24 | -105.1% | 48.9% | ||
| Q3 24 | -104.6% | 28.0% | ||
| Q2 24 | -317.9% | 15.5% | ||
| Q1 24 | -17685.3% | 43.7% |
| Q4 25 | 10.7% | 0.1% | ||
| Q3 25 | 16.1% | 0.1% | ||
| Q2 25 | 12.4% | 0.1% | ||
| Q1 25 | 12.6% | 0.0% | ||
| Q4 24 | 5.7% | 0.4% | ||
| Q3 24 | 3.9% | 0.1% | ||
| Q2 24 | 1.4% | 0.1% | ||
| Q1 24 | 583.4% | 0.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.72× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -6.27× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.26× | ||
| Q2 24 | — | 2.81× | ||
| Q1 24 | — | 5.64× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
OLPX
| Sales Channel Directly To Consumer | $43.6M | 42% |
| Sales Channel Through Intermediary Professional | $36.8M | 35% |
| Sales Channel Through Intermediary Specialty Retail | $24.7M | 23% |
